HCP Live October 4, 2024
After a historic third quarter, which saw noteworthy US Food and Drug Administration (FDA) approvals for schizophrenia, COPD, IgA nephropathy, and more, some of the year’s most anticipated decisions take place during the final 3 months of 2024. With several high-impact agents and therapies under review, both patients and healthcare providers are poised to witness decisions that could shape care for decades.
To help our audience stay informed, we have curated a list of 5 highly anticipated approvals expected by year-end, along with related content from our past coverage as well as sister publications within the MJH Life Sciences family.
Acoramidis (BridgeBio Pharma)
PDUFA: November 29, 2024
Acoramidis, a next-generation, orally administered, highly potent, small molecule stabilizer of transthyretin, has...
Today's Sponsors
Today's Sponsor